Pluri Inc

Pluri Inc a biotechnology company focuses on the development of placentabased cell therapy product candidates for the treatment of multiple inflammatory muscle injuries and hematologic conditions The company develops placental expanded PLX based cell therapy products including PLXPAD that is in Phase III clinical trials for the muscle recovery after surgery for hip fracture in Phase II clinical trails for the treatment of acute respiratory distress syndrome associated with COVID19 and in Phase III clinical trial for treatment of steroidrefractory graft versus host disease It also develops PLXR18 for incomplete hematopoietic recovery following hematopoietic cell transplantation as well as a solution for the treatment of acute radiation syndrome The company was formerly known as Pluristem Therapeutics Inc and changed its name to Pluri Inc in July 2022 Pluri Inc was incorporated in 2001 and is based in Haifa Israel